mRNA-decapping enzyme 1A (DCP1A)

mRNA-decapping enzyme 1A (DCP1A) is an enzyme found in humans that plays a central role in the removal of the 5’ cap structure from messenger RNA (mRNA) molecules, a key regulatory step in general and regulated mRNA decay[1][3][4]. DCP1A forms a decapping complex with DCP2, acting as an essential activator and scaffold, facilitating both normal mRNA turnover and quality control via nonsense-mediated decay[1][2]. DCP1A is also a critical component of cytoplasmic processing bodies (P-bodies), dynamic ribonucleoprotein granules involved in mRNA turnover, storage, and translational repression[5]. Through protein-protein interactions, especially via its N-terminal EVH1 domain, DCP1A connects mRNA decay machinery to broader signaling pathways, including TGF-beta/SMAD4 signaling and the innate immune response by activating PKR, thereby affecting translation control and antiviral defense[2][5]. Dysregulation or mutation of DCP1A is associated with diverse diseases such as cancer, certain genetic developmental disorders, and neurodegenerative diseases[3]. It is not currently a direct drug target, but modulation of its activity or interactions may represent a strategy for future therapeutic interventions.

Other names

SMIFHSA275986SMAD4IP1Smad4-interacting transcriptional co-activatorTranscription factor SMIFNbla00360DCP1 decapping enzyme homolog ADCP1 decapping enzyme-like protein Adecapping enzyme hDcp1a

Not directly targeted by drugs as of now. Mechanisms involve modulation of its enzymatic decapping activity or disruption of its protein-protein interactions (potential future strategies)